Stock Market Down, But These 3 Biotechs Up Big

The S&P 500 hit its last all-time high back at the end of 2014 and is chopped lower since. As a matter of fact, yesterday brought a new intraday low for the decline.

The Nasdaq Composite has faired a bit better over that stretch, but the index still has yet to hit a new bull market high since the end of December.

Through this period of choppy volatility, the perception is that all stocks have declined, and that most certainly isn’t the case. Actually, some stocks have performed very well in the face of market turbulence.

As has been the case for years now, some of the best performers have come from the biotech industry. The list of stocks that will be highlighted today is that of the 3 top performing biotech stocks over the last month.

The 3^rd best performing biotech stock over the last 30 days has been Array Biopharma, Inc. ARRY.

Array focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer.

About a month ago Array was trading at about $4.50/share, but since then the stock has skyrocketed to the tune of a 48 percent increase.

The 2^nd best performer on our list is Tekmira Pharmaceuticals, Corp. TKMR.

Tekmira and large moves seem to go hand in hand. At the start of January Tekmira was trading near $15/share. Now the stock is up 70+ percent from there and currently trades around $25/share.

The top dog on our list of best performing biotech stocks is ZIOPHARM Oncology, Inc ZIOP.

ZIOPHARM focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology.

The stock itself was only trading around $5/share about a month ago, but at yesterday’s close the stock is near $9/share. That’s an 80 percent rise for ZIOPHARM.

Obviously, investors must conduct their own due diligence before investing in any stock, but stocks that outperform now could very well be the names that outperform when the overall market begins to rally again.

The biotech stocks considered for this review were confined to those over $5 per share that traded at least 500K shares a day based on a 90-day average.